TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 recep...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Palmblad, Jan, Björkholm, Magnus, Kutti, Jack, Lärfars, Gerd, Löfvenberg, Eva, Markevärn, Berit, Merup, Mats, Mauritzson, Nils, Westin, Jan, Samuelsson, Jan, Birgegård, Gunnar
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2008
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2293642/
https://ncbi.nlm.nih.gov/pubmed/18414650
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars